Trial Profile
A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage II-IV HIV-Associated Hodgkin Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Sep 2023
Price :
$35
*
At a glance
- Drugs Brentuximab vedotin (Primary) ; Dacarbazine; Doxorubicin; Vinblastine
- Indications Hodgkin's disease
- Focus Adverse reactions; Therapeutic Use
- 25 Sep 2023 Status changed from active, no longer recruiting to completed.
- 11 Aug 2022 Planned End Date changed from 30 Jun 2022 to 30 Jun 2023.
- 06 Apr 2022 Planned End Date changed from 31 Dec 2021 to 30 Jun 2022.